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Since the publication of two landmark articles in 2002,1,2
he practice of controlling a patient’s core temperature after
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c-nd/4.0/).resuscitation from cardiac arrest has been an important therapeu-
tic option. Targeted Temperature Management (TTM), previously
known as therapeutic hypothermia or protective hypothermia,3 is
well recognized and accepted as part of post-resuscitative care.4,5 It
involves active treatment that tries to achieve and maintain a spe-
ciﬁc body temperature for a speciﬁc duration in an effort to improve
neurologic outcomes.
Since the publication of these articles there has been exten-
sive research published with the goal of better elucidating the
target population and reﬁnement of the technique. Much has
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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een published since the previous Canadian Guidelines in 2006,6
hich predated the use of the Grading of Recommendations
ssessment, Development and Evaluation (GRADE) Working Group
ecommendations.7 The 2010 International Liaison Committee on
esuscitation (ILCOR) guidelines5 recommend TTM as a component
f post-resuscitation care, but do not address some of the spe-
iﬁc implementation issues faced by clinicians. The publication of a
arge randomized trial8 in 2013 has stimulated further discussion,
ebate, and clinical uncertainty.
Given the advancing literature base, we revised the Canadian
uidelines to ensure that they reﬂect the current evidence. The
uidelines that follow were developed as a practical guide for clini-
ians. They are meant to address the treatment decisions physicians
ace when deciding whether to use TTM, when caring for the cooled
atient, and when prognosticating after TTM. Although TTM has
een studied for other pathologies and in pediatric age groups,
e addressed only the use of TTM after cardiac arrest in adult
atients.
The care of post-resuscitation patients can involve a number
f clinical environments and provider groups. It is important that
hese groups share a similar approach. Hence, these guidelines were
eveloped by a committee, with representation from the Canadian
ssociation of Emergency Physicians (CAEP), the Canadian Criti-
al Care Society (CCCS), the Canadian Neurocritical Care Society
CNCCS), and the Canadian Critical Care Trials Group (CCCTG). The
urpose of these guidelines is to advise clinicians with evidence
ased recommendations from informed experts with consideration
f current research, Canadian values, our health care system, and
he range of clinical environments where TTM may  be used.
ethods
We  used the GRADE9–13 and the AGREEII14 (Appraisal of Guide-
ines for Research & Evaluation II) recommendations to inform
he TTM guideline development process. The methodology was
pproved by representatives of the four contributing organizations.
ach Society had representation on the guideline committee from
he beginning of the process.
The Chair and all 13 members of the guideline committee were
equired to declare potential conﬂicts at the beginning of the
roject and again before each stage of the Delphi process. Potential
onﬂicts were shared with all members of the committee. None of
he members were from industry; there was no industry funding or
resence during any portion of the guideline development process.
upport for the project came from an unrestricted grant from the
ingston Resuscitation Institute.
A working group created a draft set of clinical questions. Cli-
icians representing community, tertiary, and academic centers
rom across Canada were asked for additional clinical questions
sing online surveys. The complete set of questions was  organized
nto categories and assigned to a section lead. The guideline com-
ittee was comprised of the Chair and eight section leads. Section
eads were responsible for coordinating the work of their team in
he literature search, extraction and grading of the literature, and
ormulation of the draft recommendations.
Individual literature searches addressed each clinical question.
he variable nature of the clinical questions precluded the use of a
ingle search strategy, but a sample search strategy was  provided
o section leads to promote consistency and uniform rigor. Sec-
ion leads developed the literature searches with the assistance of
 medical librarian or other individual trained in medical search
trategy development. Searches were performed using EMBASE,
edline, Cochrane database of Systematic Reviews, Cochrane Cen-
ral Register of Controlled Trials and the Cochrane Methodology
egister databases from inception to December 31, 2013. Titlesion 98 (2016) 48–63 49
and abstracts of the search results were scanned by two  indepen-
dent reviewers for each section. Articles identiﬁed for inclusion by
at least one reviewer underwent detailed review by both review-
ers. Additional references were sought from personal libraries of
the section authors, and by scanning the references of systematic
reviews, meta-analyses, and included articles.
Articles were summarized on a standardized extraction form
that included the abstract, identiﬁcation of industry funding, level
of evidence, and reviewer comments. A level of evidence was
assigned to individual articles using a standardized assessment
tool15 (Fig. 1).
Section leads then drafted recommendations for each clinical
question based on their review of the literature. Draft recommen-
dations, the extracted literature review results and the lead authors’
conﬂict of interest statements were circulated to the guideline
committee. To achieve our goal of developing clinically help-
ful guidelines, equivocal recommendations were avoided where
possible. When the quality of evidence was low we  considered
physiologic rationale and clinical expertise.
The committee used a combination of Delphi methodology and
nominal group technique modiﬁed from Jaeschke16 and Hsu17 to
develop the ﬁnal recommendations. Early rounds were conducted
electronically and by teleconference. The ﬁnal round was con-
ducted as an in-person meeting of all section leads during a two-day
period in September 2014.
The guideline committee considered the body of literature to
assign a ‘Quality of Evidence’ designation for each recommenda-
tion. Committee members were asked to consider the likelihood
that future evidence might change the recommendation. The level
of evidence for each article, the directness of the evidence, consis-
tency and quantity of evidence were considered when making a
designation of high, moderate, low or very low (Fig. 2). The com-
mittee consolidated the “low” and “very low” designations in to a
single “low” category for clarity.18
Recommendations were identiﬁed as strong or conditional
based on consideration of the quality of the evidence, balance
between desirable and undesirable outcomes, Canadian societal
values of potential outcomes, feasibility and cost. Fig. 3 pro-
vides further details on how the committee considered these
factors.
The voting process conducted by members of the guideline
committee was  anonymous during the electronic Delphi process
and transparent during the in-person meeting. The ﬁnal word-
ing of each recommendation was  achieved through consensus. For
clarity, the phrase “We  recommend. . .”  was  reserved for strong
recommendations and “We  suggest. . .”  for conditional recommen-
dations. A priori, it was decided that assignment of the quality of
evidence would require a simple majority, but that the strength
of a recommendation would require an 80% majority for a strong
recommendation. Members were required to be present and to par-
ticipate in the discussion of a recommendation to be entitled to vote
at the in-person meeting.
The draft manuscript was  circulated to all members of the com-
mittee for ﬁnal editorial suggestions. An independent reviewer who
was not involved in the development of the guidelines reviewed the
document using the AGREE II assessment tool. The ﬁnal manuscript
was submitted to the sponsoring Societies for endorsement. The
Canadian Association of Emergency Physicians (CAEP) initially
reviewed a draft of the guidelines but we  were unable to complete
their internal review process before publication.Recommendations
The clinical questions and recommendations of the committee
are summarized in Table 1.
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Fig. 1. Determination of level of evidence for each individual publication. Adapted from Dellinger.15
Fig. 2. Deﬁnitions for Quality of Evidence used for a Recommendation. Adapted from Guyatt.9
Fig. 3. Deﬁnitions used by the committee to assign the strength of a recommendation. Adapted from Jaeschke16 and Guyatt.10
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Table  1
Summary of recommendations CT—computed tomography, ECG—electrocardiogram, EEG—electroencephalogram, MAP—mean arterial pressure, N/A—not applicable,
PEA—pulseless electrical activity, ROSC—return of spontaneous circulation, TTM—Targeted Temperature Management, VF—ventricular ﬁbrillation, VT—ventricular
tachycardia.
Clinical question Recommendation Strength of
recommendation
Quality of
evidence
Should I use TTM in my clinical
practice?
We recommend that TTM be used for neuro-protection in eligible
adult patients after resuscitation from cardiac arrest
Strong High
Which presenting rhythms are eligible
for TTM?
We recommend that patients with a presenting rhythm of VF or
pulseless VT are eligible for TTM
Strong High
We  suggest that patients with a presenting rhythm of PEA or
asystole are eligible for TTM
Conditional Low
Are  in-hospital and out-of-hospital
patients eligible for TTM?
We recommend that patients who  suffer out-of-hospital cardiac
arrest are eligible for TTM
Strong High
We  recommend that patients who  suffer in-hospital cardiac arrest
are eligible for TTM
Strong Low
Can  TTM be used after cardiac arrest
from non-cardiac causes?
We recommend that patients who  suffer a cardiac arrest of known
cardiac cause or of an unknown cause are eligible for TTM
Strong High
We  suggest that patients who suffer a cardiac arrest from a
non-cardiac cause are eligible for TTM
Conditional Low
Can  TTM be used in pregnant women? We suggest that pregnant patients are eligible for TTM Conditional Low
Should I obtain a CT scan prior to
instituting TTM?
We recommend that imaging of the brain is not routinely required
before the initiation of TTM
Strong Low
What  constitutes unresponsiveness for
eligibility for TTM?
We recommend that patients who are comatose and do not respond
to verbal commands after cardiac arrest be considered for TTM
Strong Low
How  long should I wait after ROSC
before assessing responsiveness?
We recommend that assessment of a patient’s level of
consciousness for the purpose of determining eligibility for TTM
should be completed without delay after ROSC
Strong Low
What  are the contraindications for the
use of TTM?
We recommend that uncontrolled bleeding and refractory shock be
considered contraindications for TTM
Strong Low
We  suggest that hypotension (MAP < 60 mmHg) is not an absolute
contraindication to TTM. We suggest aggressive resuscitation of the
patient with the aim of improving MAP  and perfusion
Conditional Low
We  suggest that patients with severe infection do not undergo TTM Conditional Low
We  recommend that advanced age is not a contraindication for TTM Strong Low
We  recommend that the need for urgent coronary angiography or
percutaneous coronary intervention should not be considered a
contraindication for TTM
Strong Low
Can  TTM be used in patients in
‘electrical storm’?
We suggest that recurrent ventricular ﬁbrillation or ventricular
tachycardia not be considered a contraindication to TTM
Conditional Low
What  consultations are required prior
to instituting TTM?
We recommend that TTM be initiated by the ﬁrst provider
knowledgeable and trained in the process, and that consultation
with any particular specialty provider prior to the initiation of TTM
is  not required
Strong Low
What  settings are reasonable for
initiating TTM? Should patients be
transferred to specialized centers
before receiving TTM?
We recommend that TTM can be initiated in any medical
environment with the necessary supports, including prehospital,
emergency department, and critical care unit
Strong Moderate
How  soon should TTM be initiated? We  recommend that clinicians attempt to achieve target
temperature as rapidly as possible
Strong Low
How  late can TTM be started with a
reasonable expectation of an effect?
We  suggest that in situations where there has been an unavoidable
delay, there may be beneﬁt from TTM eight or more hours after
ROSC
Conditional Low
What  temperature should patients be
cooled to?
We suggest that patients undergoing TTM be cooled to a target
temperature between 32 ◦C and 34 ◦C
Conditional High
How  should core temperature be
monitored?
We recommend that core temperature be continuously monitored
during the cooling and rewarming phases of TTM
Strong Low
We  recommend that esophageal, nasopharyngeal, bladder,
endotracheal cuff and pulmonary artery temperature sensors are
acceptable options for monitoring core temperature
Strong Moderate
What  is the best method to use to cool
patients?
We  do not recommend a speciﬁc cooling method for TTM N/A Low
Should TTM patients receive seizure
prophylaxis?
We  suggest against the routine use of anticonvulsant medications
for seizure prophylaxis in patients undergoing TTM
Conditional Low
Should TTM patients have an EEG? We  suggest that patients who  undergo TTM receive continuous EEG
monitoring where it is available
Conditional Low
Do  all TTM patients require sedation
and analgesia?
We recommend that patients undergoing TTM should receive
sedation and analgesia
Strong Low
Do  all TTM patients require paralytic
agents?
We suggest that paralytics be used during induction and
rewarming phases of TTM, to facilitate tight temperature control
and to prevent shivering
Conditional Low
What  ECG abnormalities can be
expected from TTM and how should
they be treated?
We suggest monitoring of the QTc interval in patients undergoing
TTM
Conditional Low
We  suggest cautious use of medications that may  prolong the QTc
interval in patients undergoing TTM
Conditional Low
We  suggest that anti-arrhythmic agents be used only for the
treatment of malignant or hemodynamically signiﬁcant
arrhythmias
Conditional Low
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Table 1 (Continued )
Clinical question Recommendation Strength of
recommendation
Quality of
evidence
What should be done when patients
undergoing TTM develop
hemodynamic instability?
We suggest that hemodynamic instability developing during TTM
that is refractory to aggressive resuscitation be considered a cause
for discontinuing therapy
Conditional Low
How  should I treat bradycardia in the
patient undergoing TTM?
We suggest that bradycardia during TTM not be treated routinely
unless it is causing hemodynamic instability
Conditional Low
How  should I deal with hypokalemia in
the patient undergoing TTM?
We suggest that potassium levels be kept above 3.0 mmol  l−1
during the hypothermic phase of TTM
Conditional Low
Should patients undergoing TTM
receive prophylactic antibiotics?
We suggest against the routine use of prophylactic antibiotics in
patients treated with TTM
Conditional Low
Can  Procalcitonin be used to monitor
for infection in patients undergoing
TTM?
We recommend against the use of Procalcitonin for the diagnosis of
infection in patients treated with TTM
Strong Low
Should be have a care bundle for our
TTM patients?
We suggest that standard order sets and care bundles be utilized
for the initiation and care of patients undergoing TTM
Conditional Low
Should patients undergoing TTM be
fed?
We  recommend that patients undergoing TTM receive enteral
nutrition
Strong Moderate
We  suggest that caloric intake targets be calculated as 75% of
normothermic targets during the hypothermic phase of TTM if
calorimetry is not being used
Conditional Low
When  should rewarming be initiated? We  suggest that rewarming should begin 24 h after the patient
reaches the target temperature
Conditional Low
How  rapidly should TTM patients be
rewarmed
We  suggest that patients should be rewarmed at a rate of
0.25–0.5 ◦C per hour
Conditional Low
How  should fever be managed after
rewarming from TTM?
We  suggest that hyperthermia should be prevented for at least 72 h
post arrest
Conditional Low
How  long after ROSC should I wait
before prognosticating in patients who
have received TTM?
We recommend that a clinical neurologic examination for the
purpose of prognostication not be performed earlier than 72 h after
return of spontaneous circulation
Strong Moderate
We  suggest that when there is a concern of residual medication
effect, clinical neurologic examination for prognostication should
be deferred until the clinician is conﬁdent that the confounding
effects are no longer present
Conditional Low
What  adjunctive testing is required to
make a prognosis after the use of TTM?
We  suggest that adjunctive testing is not routinely required to
identify poor neurological outcome in patients after TTM
Conditional Low
We  suggest that somatosensory evoked potentials and continuous
EEG can facilitate prognostication in speciﬁc circumstances
Conditional Low
Is  consultation with a neurologist We recommend that a neurologic consultation is not routinely
r the 
Strong Low
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ndications and Contraindications
e recommend that Targeted Temperature Management (TTM)
e used for neuro-protection in eligible adult patients after
esuscitation from cardiac arrest.
Quality of evidence: High
Strength of recommendation: Strong
e recommend that patients with a presenting rhythm of ven-
ricular ﬁbrillation (VF) or pulseless ventricular tachycardia (VT)
re eligible for TTM.
Quality of evidence: High
Strength of recommendation: Strong
e suggest that patients with a presenting rhythm of pulseless
lectrical activity (PEA) or asystole are eligible for TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
The highest level of evidence we identiﬁed that addressed
hether or not to use TTM was from two randomized controlled
rials (RCTs).1,2 These trials demonstrated a decrease in mortality
nd improvement in neurologic outcome in patients with a pre-
enting rhythm of VF or pulseless VT who were treated with TTM.
he Hypothermia After Cardiac Arrest (HACA) trial2 found favorable
eurologic outcome at six-months increased from 39% in the con-
rol group to 55% in TTM group (risk ratio 1.40, 95% CI 1.08–1.81).
ernard et al.1 found that survival with good neurologic function
as 26% in the control and 49% in the TTM group (p = 0.046). The
iterature review also identiﬁed a signiﬁcant volume of lower level
vidence supporting the use of TTM after cardiac arrest.use of TTM
The committee discussed the HACA and Bernard trials
extensively. There were a number of potential ﬂaws in the method-
ology identiﬁed, which have been identiﬁed previously in the
literature,19,20 leading some committee members to downgrade
one or both of the studies to level B. After consideration of these
trials together with the large volume of observational evidence, the
committee found the quality of evidence to be high for the use of
TTM when the presenting rhythm is VF of pulseless VT.
On the basis of the quality of the evidence, treatment effect,
the value society places on neurologic function and relative cost-
effectiveness the committee arrived at a strong recommendation
for the use of TTM after cardiac arrest for patients who present
in VF or pulseless VT. Particular note was made that ‘presenting
rhythm’ may  not be the best method of stratifying cardiac arrests.
It is used as a surrogate-marker for cardiac arrest severity, patho-
genesis, or prognosis; however the basis for this is not well
established.
The committee found the quality of evidence comparing TTM to
normothermia for patients presenting with PEA and asystole to be
low. Although some evidence has reported reasonable survival8,21
the committee assigned a conditional recommendation for patients
presenting in asystole and PEA. Discussion focused on the inappro-
priate use of presenting rhythm as determinant of therapy, and
low risk of harm from TTM. The committee discussed the possibil-
ity of reduced mortality but an increase in the number of patients
with a poor neurologic outcome. The uncertainty of this possibility
and low quality of evidence in this patient group resulted in the
conditional recommendation.
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We  recommend that patients who suffer out-of-hospital car-
iac arrest are eligible for TTM.
Quality of evidence: High
Strength of recommendation: Strong
We recommend that patients who  suffer in-hospital cardiac
rrest are eligible for TTM.
Quality of evidence: Low
Strength of recommendation: Strong
The best evidence demonstrating the beneﬁcial effects of
TM enrolled patients who had suffered cardiac arrest out-of-
ospital.1,2 On the basis of this evidence, the committee assigned
 high quality of evidence and a strong recommendation for the
ligibility of these patients.
The evidence for the use of TTM for in-hospital cardiac arrest
s considerably weaker. One investigation of in-hospital cardiac
rrests found an increase in mortality from 40% to 61% (not statis-
ically signiﬁcant) when patients were treated with TTM.22 Other
tudies have not demonstrated a difference in mortality with the
se of TTM.21,23,24 Although the quality of evidence was low, the
ommittee felt that location of the cardiac arrest lacked sufﬁcient
iscriminative ability as an outcome predictor to be used to estab-
ish eligibility, and recommends that all patients who  have a cardiac
rrest, including those occurring in-hospital, be considered eligible
or TTM.
We recommend that patients who suffer a cardiac arrest of
nown cardiac cause or of an unknown cause are eligible for
TM.
Quality of evidence: High
Strength of recommendation: Strong
We suggest that patients who suffer a cardiac arrest from a
on-cardiac cause are eligible for TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
The HACA2 and Bernard1 trials included patients whose arrest
as known to be cardiac in origin, or of unknown cause. This
s also the inclusion practice for much of the observational
esearch. On the basis of this evidence, the committee arrived at
 strong recommendation for the treatment of these patients with
TM.
We did not ﬁnd the same level of evidence for arrests known to
e from a non-cardiac cause. There are small case series and case
eports describing variable neurological outcomes when TTM was
sed after cardiac arrest associated with various etiologies.25–38
 case series of 14 consecutive comatose survivors of asphyxia
hat were treated with TTM observed a survival rate of 65%.25 In
nother retrospective cohort study of 16 unconscious patients after
ear hanging, 13 patients received TTM and 12 of them had poor
eurological outcomes.38
The committee found the quality of the evidence to be low. We
ade a conditional recommendation that these patients be consid-
red eligible for TTM based on the opinion that in the absence of
ther contraindications, the anoxic brain injury suffered from the
ardiac arrest may  realize beneﬁt from TTM in the same way as
atients whose arrest was cardiac in origin. There was  signiﬁcant
oncern among committee members that this patient population
ight be more likely to have relative contraindications to TTM, but
onsidered this issue separately.
We  suggest that pregnant patients are eligible for TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
Pregnant patients were excluded from trials demonstrating ben-
ﬁt from the use of TTM.1 The quality of evidence supporting TTM in
regnant patients was found to be low. Cases of pregnant patients
ho were cooled after cardiac arrest have been reported.39–41
wo resulted in normal fetal delivery, the third in fetal
emise.ion 98 (2016) 48–63 53
The committee found that the lack of evidence and lack of
good physiologic information made addressing this clinical ques-
tion challenging. Ultimately, when faced with a pregnant patient
otherwise eligible for TTM, the majority of committee members
would cool the patient. The paucity of evidence for effect and safety
in this population and concerns for potential harm resulted in a
conditional recommendation.
We  recommend that imaging of the brain is not routinely
required before the initiation of TTM.
Quality of evidence: Low
Strength of recommendation: Strong
There was no high-level literature that evaluated this issue
directly. One prospective study42 failed to demonstrate a differ-
ence in door to cooling time when computer tomography (CT)scan
of the head was performed prior to ICU admission, compared to
after admission or not at all. The committee found the quality of
evidence for this recommendation to be low.
The consensus of the committee was that although brain imag-
ing may  play an important role in the management of these
patients at some point during their care, it is not routinely
required prior to the initiation of TTM. Routine CT scanning
prior to TTM could signiﬁcantly delay its initiation, particu-
larly in settings that require transport to another centre. It is a
reasonable option to cool simultaneously with CT scanning. In
cases where there is a strong suspicion of intracranial bleed-
ing, it is reasonable to delay TTM initiation until a CT scan is
obtained.
We recommend that patients who are comatose and do not
respond to verbal commands after cardiac arrest be considered
for TTM.
Quality of evidence: Low
Strength of recommendation: Strong
We recommend that assessment of a patient’s level of con-
sciousness (LOC) for the purpose of determining eligibility for
TTM should be completed without delay after return of sponta-
neous circulation (ROSC).
Quality of evidence: Low
Strength of recommendation: Strong
The purpose of determining level of consciousness is to iden-
tify patients without signiﬁcant neurologic injury so that TTM
may  be withheld accordingly. The timing of this assessment as a
component of TTM eligibility was not directly addressed in the lit-
erature. The reviewers looked to the HACA2 and Bernard1 studies
and found that the timing was  not well deﬁned in either study. Nei-
ther of these trials imposed an intentional delay period before the
assessment.
The reviewers looked to studies demonstrating a clinical beneﬁt
from TTM for their deﬁnition of neurologic dysfunction and found
signiﬁcant variation. In the Bernard trial,1 patients were included
if they had “persistent coma” but the term was  not further deﬁned
in the paper. In the HACA trial,2 patients were excluded if they
were able to “respond to verbal commands after ROSC and before
randomization”. In the RCT by Laurent et al.,43 patients were not
randomized if they were found to respond to verbal commands
after ROSC.
The committee gave this as a strong recommendation despite
the low level of evidence. This was based on the perceived
importance of avoiding delay and the very low risk of harm
in early initiation of TTM. The committee recognized it is
not uncommon for some patients to have early and rapid
improvements in LOC during the immediate period following
ROSC. If such an improvement occurs TTM could reasonably
be aborted. The committee was  particularly cognizant of the
value that members of society place on avoiding even small
neurologic insults, and the low level of risk associated with
TTM.
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We  recommend that uncontrolled bleeding and refractory
hock be considered contraindications for TTM.
Quality of evidence: Low
Strength of recommendation: Strong
We suggest that hypotension (MAP < 60 mmHg) is not an
bsolute contraindication to TTM. We  suggest aggressive resus-
itation of the patient with the aim of improving MAP  and
erfusion.
Quality of evidence: Low
Strength of recommendation: Conditional
We suggest that patients with severe infection should not
ndergo TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
We recommend that advanced age is not a contraindication
or TTM.
Quality of evidence: Low
Strength of recommendation: Strong
We recommend that the need for urgent coronary angiog-
aphy or percutaneous coronary intervention should not be
onsidered a contraindication for TTM.
Quality of evidence: Low
Strength of recommendation: Strong
For the purpose of identifying contraindications, the review-
rs sought reports of adverse effects and reviewed the exclusion
riteria of the articles that demonstrated beneﬁt from TTM.
leeding
Patients were excluded from the HACA study2 if they had a
known pre-existing coagulopathy”. They found that 19% in the
ormothermia group and 26% in the treatment group experienced
leeding of any kind. The difference was not statistically signiﬁ-
ant. In the Bernard study,1 patients were not excluded on the basis
f bleeding or pre-existing coagulopathy. There were no reported
leeding complications in either arm of the study. In the Nielsen
rial,44 there was no difference in bleeding detected between the
roup cooled to 36 ◦C and the group cooled to 33 ◦C.
Hypothermia induces a mild bleeding diathesis with effects on
latelet count and function, effects on clotting factors and other
omponents of the clotting cascade.45,46 The risk of bleeding must
e weighed against the potential neurologic beneﬁts on a case by
ase basis based on the severity and location of the bleeding. The
ommittee felt that it is prudent to withhold TTM in patients who
re having active signiﬁcant bleeding (e.g. severe GI bleed, intracra-
ial hemorrhage) until that bleeding is controlled.
hock
There is no data from RCTs to support the use of TTM in post car-
iac arrest patients with persistent hypotension (SBP < 90 mmHg
r MAP  < 60). There is evidence from a non-randomized study
valuating TTM to 33 ◦C for patients in cardiogenic shock who
ere not post-arrest. They found TTM resulted in reduced heart-
ate, increased MAP, increased ejection fraction, increased inotropy
nd reduced vasopressor and inotrope requirements.47 Several
ther non-randomized studies provide weak evidence demonstrat-
ng reduced or similar catecholamine requirements to maintain
lood pressure in patients treated with TTM to a goal of 32–34 ◦C
ompared with normothermic patients after cardiac arrest.48,49
ub-group analysis of one observational study found beneﬁt for
atients with shock who received TTM.50The committee considered that in some clinical situations the
eneﬁts of TTM could be outweighed by further neurologic dam-
ge due to hypoperfusion, but found little to support this occurring.
here was agreement that patients should not be cooled if theyion 98 (2016) 48–63
are persistently hypotensive despite full resuscitative efforts (e.g.
ﬂuids, inotropes, vasopressors and mechanical support as indi-
cated). Bradycardia without hypotension or hypoperfusion was
not considered a contraindication, and is expected with induced
hypothermia. The committee agreed that the need for volume
resuscitation, vasopressor or inotropic medications, or mechani-
cal support to treat shock should not be contra-indications to TTM
if reasonable blood pressure and perfusion goals can be achieved
(SBP > 90 mmHg  or MAP  > 60 mmHg).
Infection
Hypothermia impairs immune function.51–53 The effect of thera-
peutic hypothermia for patients who  suffer cardiac arrest as a result
of severe sepsis or septic shock is not known. It is conceivable that
the immune suppression caused by therapeutic hypothermia may
be beneﬁcial for patients with overwhelming sepsis by attenuat-
ing a destructive, mal-adaptive inﬂammatory response. It is also
possible that hypothermia mediated immune suppression could
be detrimental if it impairs the ability to clear infection.
The committee members felt that sepsis and septic shock should
be considered relative contra-indications to TTM because of a lack
of demonstrated beneﬁt and concern for potential harm.
Age
There is a paucity of evidence for the use of TTM in the elderly
(>75 years). Elderly patients were excluded from the HACA trial.2
Patients in the Bernard study1were as old as 89, but the number
of included patients >75 is not clear. At least one case series54 has
reported outcomes in an elderly group of patients. In 30 patients
>75, half of them had “good neurologic outcome”.
It was  the opinion of the committee that without evidence or
biologic rationale for increased harm from TTM in the elderly,
age alone should not be considered a contraindication to TTM.
Co-morbidities, baseline quality of life and previously expressed
wishes must be considered carefully when determining suitability
for all aggressive critical care, including TTM.
Percutaneous coronary interventions
Several reports have demonstrated the feasibility and poten-
tial beneﬁt of performing urgent angiography and percutaneous
coronary intervention in conjunction with TTM for patients with
suspected ACS causing cardiac arrest.55–57 These small, non-
randomized reports provide low level evidence to suggest that TTM
can be induced prior to and during PCI without delaying door-to-
balloon time.
Although there has been concern expressed that hypothermia
may  result in increased myocardial irritability, this has not been
demonstrated at temperatures above 30 ◦C. There is some sugges-
tion that core temperatures in the target range may, in fact, result
in membrane stabilization.
The committee members were of the opinion that TTM should
be initiated as soon as possible for eligible patients, including those
requiring urgent coronary angiography. There is no need to delay
TTM for PCI.
We suggest that recurrent ventricular ﬁbrillation or ventri-
cular tachycardia not be considered a contraindication to TTM.
Quality of evidence: Low
Strength of recommendation: ConditionalDespite being a high risk population, clinically signiﬁcant car-
diac arrhythmias are rare in patients treated with TTM.1,2,58,59
Animal and human studies have demonstrated both a reduction
in the electrical threshold required for successful deﬁbrillation,
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s well as improved deﬁbrillation success during hypothermic
esuscitation.60–62
The committee felt that given the lack of evidence to suggest
arm and the potential for neurologic beneﬁt from TTM, it would
e reasonable to initiate or maintain TTM in patients with recurrent
F/VT. Based on the low level of evidence the committee assigned
 conditional strength of recommendation.
We  recommend that TTM be initiated by the ﬁrst provider
nowledgeable and trained in the process, and that consultation
ith any particular specialty provider prior to the initiation of
TM is not required.
Quality of evidence: Low
Strength of recommendation: Strong
There is no data from controlled studies examining the effect
f one type of care provider over another with respect to the
nduction of TTM for post cardiac arrest syndrome. Feasibility of
TM induction for post cardiac arrest patients has been demon-
trated by studies set in the prehospital, emergency department,
atheterization laboratory and intensive care settings. Paramedics,
mergency physicians, cardiologists and critical care specialists
ave all demonstrated the ability to initiate TTM.
Despite the low quality of evidence supporting this recom-
endation, the committee felt that a strong recommendation was
mportant to emphasize that routine delay in initiating TTM in order
o defer the care to another group of care givers creates an unneces-
ary barrier and may  not be in the patient’s best interest. In complex
r confounded situations, consultation with a specialist may  be very
elpful and is appropriate.
We  recommend that TTM can be initiated in any medical
nvironment with the necessary supports, including prehospi-
al, emergency department, and critical care unit.
Quality of evidence: Moderate
Strength of recommendation: Strong
The reviewers found nine articles63–71 that addressed TTM use
utside of the intensive care unit. Most were in the prehospital
etting, and most suggested both safety and feasibility.
The committee discussed the implications of the study by Kim67
hat compared a treatment group that received two liters of 4 ◦C
aline in the prehospital setting compared to a control group cooled
n hospital using surface or intravascular cooling. There was no dif-
erence in survival or neurologic outcome; however there were
uggestions of harm with the treatment group experiencing a
igher rate of re-arrest and early pulmonary edema. The commit-
ee attributed the signal of potential harm to the use of cold saline
ather than the initiation of cooling in the prehospital setting.
It was the opinion of the committee that with appropriate train-
ng and support, TTM can be safely provided in a variety of medical
nvironments. The strength of the recommendation was based on
he potential beneﬁt to patients from the therapy and the impor-
ance of removing setting as a barrier to quality care.
iming
We  recommend that clinicians attempt to achieve target
emperature as rapidly as possible.
Quality of evidence: Low
Strength of recommendation: Strong
The reviewers were unable to identify any high quality studies
hat directly compared one time target to another time target. Nine
tudies involved time to target TH/TTM temperature.1,2,70,72–77 One
etrospective study73 found a worse outcome with quicker time to
arget temperature. There was no evidence incorporating an inten-
ional delay in the initiation of hypothermia.
When considering the evidence, the committee chose not to give
igniﬁcant weight to the ﬁndings of retrospective and observationalion 98 (2016) 48–63 55
studies due to the confounding issue of injury severity. There was
concern that patients with more severe neurologic injury at ROSC
may  have disordered autonomic function, including impaired ther-
moregulation. These patients would be expected to have a lower
temperature at presentation and cool more quickly, resulting in a
shorter time to target temperature.
When making the recommendation the committee spent con-
siderable time discussing the timing of therapy in trials that showed
beneﬁt from TTM, as well as the impact of time delay on the mech-
anisms proposed for TTM beneﬁt. The strong recommendation was
delivered despite the low quality of evidence based on the concern
that any delay may  result in progressive decrease in beneﬁt, while
the risk of harm probably remains constant.
We  suggest that in situations where there has been an
unavoidable delay, there may  be beneﬁt from TTM eight or more
hours after ROSC.
Quality of evidence: Low
Strength of recommendation: Conditional
There are clinical situations when there is a signiﬁcant delay
between ROSC and the opportunity to induce TTM. These could
include transport from a site that did not provide TTM or delays
for procedures. The reviewers did not ﬁnd any literature involving
an intentional time delay after ROSC before initiating cooling. The
HACA trial,2 which demonstrated a survival and neurologic beneﬁt,
had a median time to target of 8 h (interquartile range 4–16 h).
The committee did not set a time period after which patients
should not be cooled, but found it likely that the beneﬁts of TTM
decrease with time.
Cooling process
We  suggest that patients undergoing TTM be cooled to a tar-
get temperature between 32 ◦C and 34 ◦C.
Quality of evidence: High
Strength of recommendation: Conditional
The target temperature of 32–34 ◦C became the standard of care
based primarily on the two studies published in 20021,2 and further
supported by three other studies that showed beneﬁt of cooling to
this range compared to no cooling.78–80 The choice of tempera-
ture target in these studies was  extrapolated from animal data, and
demonstrated beneﬁt when compared to no temperature control.
Three studies have speciﬁcally assessed the target temperature for
therapeutic hypothermia after cardiac arrest.8,81,82 None of these
studies demonstrated that a different target temperature leads to
improved survival or neurologic outcomes. This issue generated
extensive discussion. The primary issue debated by the commit-
tee was whether to extend the range from 32–34 ◦C to 32–36 ◦C
based on the results of the trial published by Nielsen et al. in 2013.8
This was a large multicenter randomized controlled trial compar-
ing a target of 36 ◦C to 33 ◦C, with a primary endpoint of all-cause
mortality to the end of the trial. It was the largest RCT on TTM
to date, enrolling 950 patients from 36 intensive care units. They
found a hazard ratio with a target temperature of 33 ◦C of 1.06 (CI
0.89–1.28; p = 0.51).
The trial was  designed and analyzed as a superiority trial. It
is generally not appropriate to use a superiority trial to con-
clude equivalence or non-inferiority,83 but the trial’s close point
estimates and large size has led some to conclude effective
demonstration of non-inferiority.84,85 There are design and anal-
ysis requirements for a trial to demonstrate non-inferiority, well
described by the Consolidated Standards of Reporting Trials (CON-
SORT) group83,86 and others.87–89 Ultimately, the committee found
the study inappropriate for a ﬁnding of non-inferiority because of
the absence of a deﬁned margin of inferiority, inappropriate inclu-
sion criteria, and a study design lacking assay sensitivity.
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In noninferiority and equivalence trials, a prestated margin of
oninferiority for the treatment effect in each outcome is deﬁned.83
t is in relation to this margin that the analysis is expressed. It
s usually based on a proportion of the beneﬁt that the standard
roup previously demonstrated over placebo, but also requires
ome judgement as to what would be considered clinically mean-
ngful. The conﬁdence intervals in the Nielsen trial include results
hat some might consider clinically important.
Enrollment of patients in a noninferiority trial should match as
losely as possible the enrollment of the trials when the reference
reatment demonstrated superiority over controls.83 A broader
nrollment increases the likelihood of incorrectly concluding non-
nferiority. The Nielsen trial included patients that would not have
een included in the Bernard or HACA trials, resulting in a study that
ore closely matches clinical practice but more likely to incorrectly
onclude noninferiority.
Assay sensitivity refers to the ability of a speciﬁc clinical trial
o demonstrate a difference if such a difference truly exists, and is
erhaps the greatest challenge for noninferiority trials.88 When a
uperiority trial demonstrates an effect it also proves assay sensi-
ivity, but this is not true for a noninferiority trial. The Nielsen trial
ad design elements appropriate in a superiority trial but inap-
ropriate when analyzing for noninferiority. The committee made
peciﬁc note that the intervention (cooling) was not standardized in
ts method or the rate achieved; there was a signiﬁcant delay after
OSC before initiation of temperature control; and rewarming was
apid compared to previous trials.
The signiﬁcance of each of these issues is unclear, but when con-
idered together the committee found it inappropriate to conclude
oninferiority of a target temperature of 36 ◦C.
The committee also looked for a compelling reason to extend
he target. We did not ﬁnd a reduction in cost or resources by tar-
eting 36 ◦C. We  found no evidence of harm reduction to patients
y targeting 36 ◦C. There was no reduction in adverse events by
argeting 36 ◦C (speciﬁcally there was no signiﬁcant differences
ound in adverse events including bleeding, infection and arrhyth-
ias from the Nielsen data). The committee also discussed the
reater risk of potential hyperthermia due to drift when select-
ng a higher target temperature. For these reasons, the committee
ound insufﬁcient cause to extend the recommended targeted
emperature range. When considering the overall quality of the
vidence for this recommendation, the committee discussed and
onsidered the methodological shortcomings of the HACA and
ernard trials. The potential for bias in these studies has been
ell discussed elsewhere,19,20 and the committee was particularly
oncerned about the potential role that unblinded palliation deci-
ions might have had. These limitations were recognized, but when
onsidered in combination with the volume of lower quality sup-
orting research the committee voted to assign a “high” quality
or the evidence for the 32–34 ◦C target range. It does not refer
o the evidence for what the precise target temperature should
e. In assigning strength to the recommendation, 63% of the vot-
ng members were in favor of a strong recommendation. This was
elow our a priori requirement of an 80% majority for a strong
ecommendation, and so the recommendation was assigned a ‘con-
itional’ strength. Those in favor of the strong recommendation
id so based on the quality of evidence, lack of harm, the soci-
tal value placed on survival and improved neurologic outcome,
he size of the treatment effect, as well as the feasibility and low
ost of the recommendation. The dissenting opinion was  based
rimarily on acceptance of the Nielsen trial, uncertainty whether
uture research might demonstrate that a higher target tempera-
ure is safer for patients, or easier for physicians to achieve and
aintain.
Our understanding of target temperature is still immature. We
ight expect that there is a dose effect with a therapeutic rangeion 98 (2016) 48–63
for temperature management. There may  be a subset of patients
who become hemodynamically unstable at the usual target who
may tolerate and beneﬁt from a target of 36 ◦C, but the committee
concluded that there is currently not sufﬁcient evidence to change
the standard ‘dose’ of 32–34 ◦C.
We recommend that core temperature should be continu-
ously monitored during the cooling and rewarming phases of
TTM.
Quality of evidence: Low
Strength of recommendation: Strong
We recommend that esophageal, nasopharyngeal, bladder,
endotracheal cuff and pulmonary artery temperature sensors
are acceptable options for monitoring core temperature.
Quality of evidence: Moderate
Strength of recommendation: Strong
No studies have attempted to induce TTM without continu-
ous measurement of core temperature. Continuous monitoring is
important to avoid signiﬁcant time spent outside the target tem-
perature range.
One observational study of cardiac arrest patients found that
esophageal, pulmonary artery and endotracheal tube cuff sen-
sor measurements were similar,90 while a second found that
pulmonary artery, bladder and nasopharyngeal temperature mea-
surements were well correlated.91
Two studies were performed in cardiopulmonary bypass
patients. One found that esophageal, nasopharyngeal and pul-
monary artery assessments had the closest correlation to cerebral
temperature.92 The second paper found that nasopharyngeal
temperatures did not correspond well to arterial temperature
measurements.93
A case report examined various temperature measurements in
a conscious subject undergoing induced hypothermia,94 and found
that esophageal monitoring most closely approximated pulmonary
artery temperatures during cooling and rewarming.
Rectal probes have been reported to correlate poorly with
esophageal temperature probes95 and to be less accurate during
rewarming phases.94 Tympanic measurements have been found to
not be accurate when ice packs are applied to the head and neck,96
and may  also be inaccurate during rewarming.94
We  do not recommend a speciﬁc cooling method for TTM.
Quality of evidence: low
Strength of recommendation: no recommendation
The literature review found a number of feasible cooling
methods,1,32,43,69,97–117 however no speciﬁc method of cooling has
been shown to improve patient outcomes.
Methods vary signiﬁcantly in terms of ease of use, time to tar-
get temperature, temperature variability, cost and availability. It
is common to use multiple cooling methods to achieve TTM. Cli-
nicians should consider having a protocol individualized for their
institution based on patient factors, ease of use, cost and local
resources.
The committee was unable to make a speciﬁc recom-
mendation on cooling method due to the range of clinical
settings in which this therapy will be used. Surface cool-
ing with ice-packs continues to be an acceptable method of
inducing TTM, and is feasible in almost all clinical settings.
Centers with resources and sufﬁcient frequency might achieve
shorter time to target temperature, tighter temperature control
and improved convenience using commercially available cooling
devices.
As discussed previously, the trial by Kim67 suggests potential
harm from using 4 ◦C saline as a component of a cooling strategy.
The trial compared a treatment group that received two  liters of 4 ◦C
saline in the prehospital setting compared to a control group cooled
in-hospital using surface or intravascular cooling. There was  no dif-
ference in survival or neurologic outcome, however the treatment
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roup experienced a higher rate of re-arrest and early pulmonary
dema.
are of TTM patient
We suggest against the routine use of anticonvulsant medi-
ations for seizure prophylaxis in patients undergoing TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
There were no high level studies found in the review directly
ddressing the question. Nine observational studies were reviewed
eporting on 1199 patients that addressed the occurrence of seizure
uring TTM. On meta-analysis the cumulative incidence of seizures
as 20.2% (95% CI 15.4–25.4%, I2 = 63%).118–126 There was signif-
cant heterogeneity in the incidence of seizures likely reﬂecting
ifferent patient populations and sedative regimens.
The committee considered that the use of sedative regimens
ith anticonvulsant activity is common in patients undergoing
TM and that there were no studies in which prophylaxis with anti-
onvulsant medications for seizures was administered. Moreover,
he administration of enteral anticonvulsant medications may  be
roblematic in patients undergoing TTM as they require enteral
ccess, a functional gastrointestinal tract for absorption and the
rugs may  have a signiﬁcant side effect proﬁle. Anticonvulsant
edications available in parenteral formulations may  have signif-
cant side effects and can be costly.
The low quality of evidence resulted in a conditional recommen-
ation.
We suggest that patients who undergo TTM receive con-
inuous electroencephalography (cEEG) monitoring where it is
vailable.
Quality of evidence: Low
Strength of recommendation: Conditional
Most of the observational studies reporting on the incidence
f seizures utilized cEEG, although the largest one did not.123 The
ccurrence of seizures, status epilepticus, generalized suppression,
urst suppression, or an isoelectric/unreactive pattern were asso-
iated with worse outcomes in severalstudies,122,125 although the
reatment of the seizures was not reported as inﬂuencing the out-
omes.
The committee considered that TTM patients may  receive par-
lytic agents, masking the occurrence of seizures. The incidence
f seizures in this patient population is high, and there is sig-
iﬁcant potential harm of unrecognized and untreated seizures.
he committee recognized the lack of widespread availability of
EEG and signiﬁcant resources required for routine implemen-
ation, but identiﬁed potential beneﬁt to patients where already
vailable.
We recommend that patients undergoing TTM should receive
edation and analgesia.
Quality of evidence: Low
Strength of recommendation: Strong
We suggest that paralytics be used during induction and
ewarming phases of TTM, to facilitate tight temperature con-
rol and to prevent shivering.
Quality of evidence: Low
Strength of recommendation: Conditional
Two observational trials127,128 and one RCT129 addressed
edation regimens in patients undergoing TTM. Bjelland et al.
andomized 59 patients to propofol/remifentanyl vs. midazolam/
entanyl,129 and found the time to extubation was  signiﬁcantly
horter in the remifentanyl/propofol group. The small number of
atients, as well as the fact that it was not blinded and used sub-
ective endpoints was noted by the committee. Both the HACA
nd Bernard trials used sedation and paralysis for all patients
nrolled.1,2 The recent TTM trial8 used sedation and analgesia in allion 98 (2016) 48–63 57
patients during the initiation, maintenance and rewarming phases
of temperature management.
The committee reasoned that despite the low quality of evi-
dence, the use of sedation and analgesia warranted a strong
recommendation based on the low risk of harm and as a reﬂection
of patient and societal values around symptom control.
The distribution, metabolism, and clinical effect of drugs used
for sedation and analgesia are affected by hypothermia.130,131 It
is not known which agent or combination is optimal for use in
this setting.129,132 Given the low quality of evidence, the commit-
tee chose not to make a recommendation for a speciﬁc medication
combination in favor of physician familiarity with commonly used
medications.
The conditional recommendation regarding the use of paralytics
reﬂects the low quality of evidence and the perception of greater
potential harm from the overuse of neuromuscular blocking agents.
The members of the committee uniformly use paralytics during the
induction and rewarming phases, but there is signiﬁcant variation
in practice. Most members use paralytics routinely but a few only in
response to shivering. Some continue the agents during the entire
therapy. Others discontinue the agents when the core temperature
is less than 34 ◦C, a time when patients generally are unable to
mount a shivering response. There was agreement that the duration
of neuromuscular blocking agents should be minimized, however
paralysis may  eliminate shivering and permit tight temperature
control.
We  suggest monitoring of the QTc interval in patients under-
going TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
We suggest cautious use of medications that may  prolong the
QTc in patients undergoing TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
We suggest that anti-arrhythmic agents be used only for
the treatment of malignant or hemodynamically signiﬁcant
arrhythmias.
Quality of evidence: Low
Strength of recommendation: Conditional
A variety of EKG changes are observed during TTM. Osborne
waves are seen in up to 30% of patients.133,134 Prolonged QTc
intervals are common but have not been associated with malig-
nant arrhythmias.59 Additionally, no increases in other arrhythmias
have been associated with TTM.58,135 No studies of the treatment
of arrhythmias during TTM were found. The committee recognizes
that a large proportion of patients undergoing TTM will have indica-
tions for anti-arrhythmic agents based on rhythms present during
their cardiac arrest, but did not ﬁnd TTM alone to be an indication
for these medications.
We  suggest that hemodynamic instability developing during
TTM that is refractory to aggressive resuscitation be considered
a cause for discontinuing therapy.
Quality of evidence: Low
Strength of recommendation: Conditional
We suggest that bradycardia during TTM not be treated rou-
tinely unless it is causing hemodynamic instability.
Quality of evidence: Low
Strength of recommendation: Conditional
There were no randomized trials and only observational trials
regarding these issues were reviewed. Hemodynamic instabil-
ity is common in post cardiac arrest patients, including those
undergoing TTM, and is associated with worse outcomes.136Similarly, higher doses of vasopressors are associated with wors-
ened outcomes.137 There are numerous causes for post cardiac
hemodynamic instability including vasodilation, systemic inﬂam-
matory response, myocardial stunning, myocardial damage and
5 scitat
h
s
h
w
s
p
c
b
d
p
m
r
t
t
T
p
c
a
b
t
d
i
a
i
p
d
d
o
i
p
h
t
t
i
d
d
o
T
o
l
0
s
a
e
H
i
n
o
e
t
a
p
i
a
give a strong recommendation. The caloric target was downgraded
to a conditional recommendation because of uncertainty and a8 D. Howes et al. / Resu
ypovolemia. However, data from observational studies suggest
ome of these derangements can be improved by TTM.
In a propensity matched analysis, Zobel et al. found that
ypothermia in patients with cardiogenic shock was associated
ith bradycardia but maintenance of cardiac output with a reduced
ystemic vascular resistance.47 In a non-randomized design of
atients undergoing TTM, the initiation of TTM was not asso-
iated with increased vasopressor requirements or changes in
lood pressure.138 Similarly, Huynh et al. and Jacobshagen et al.
id not ﬁnd that vasopressor requirements were increased in
atients undergoing TTM.48,49 In a small study with historically
atched controls, the initiation of TTM hypothermia did not impair
esuscitation.139 There were no studies that compared or studied
he treatment of bradycardia during TTM and there were no studies
hat compared different vasopressor or inotropic regimens during
TM.
The committee’s recommendations are based on underlying
hysiological principles and clinical experience. The members con-
luded that the value of TTM is sufﬁcient that the therapy be
bandoned only in cases where hemodynamic instability cannot
e controlled by other means. It is the experience of commit-
ee members that for the majority of these patients rewarming
oes not result in stabilization. The treatment of hemodynamic
nstability during TTM, including ﬂuid therapy, vasopressors
nd inotropes should be based on the underlying physiolog-
cal derangements, as there is signiﬁcant variation between
atients.
We suggest that potassium levels be kept above 3.0 mmol  l−1
uring the hypothermic phase of TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
Patients treated with TTM have an increased risk of hypokalemia
uring the cooling phase of TTM.140 Mirzoyev et al. studied the risk
f hypokalemia in a retrospective study of 94 patients undergo-
ng TTM post cardiac arrest. Hypokalemia was associated with QTc
rolongation and polymorphic ventricular tachycardia. Rebound
yperkalemia on warming did not occur. Soeholm et al. prospec-
ively studied 54 patients and found that potassium levels dropped
o below 3.5 mmol  l−1 in 78% of TTM patients.141 Both of these stud-
es recommended that potassium levels be kept above 3.0 mmol  l−1
uring the hypothermic phase of TTM. The strength of recommen-
ation was based on the low quality of supporting evidence.
We  suggest against the routine use of prophylactic antibi-
tics in patients treated with TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
A recent meta-analysis examined the risk for infection during
TM for any indication.142 Twenty-three RCTs randomized to TTM
r usual care, including 2820 patients were included. The preva-
ence of all infections was not increased (rate ratio, 1.21 [95% CI,
.95–1.54]), but there was an increased risk of pneumonia and sep-
is (risk ratios, 1.44 [95% CI, 1.10–1.90]; 1.80 [95% CI, 1.04–3.10]). In
 retrospective review of 641 patients, 500 (78%) were treated for
arly onset pneumonia deﬁned as within 3 days of admission.143
owever, although early onset pneumonia was associated with
ncreased duration of mechanical ventilation and ICU stay, it was
ot associated with increased mortality or worsened neurologic
utcome.
One study addressed the issue of prophylactic antibiotics. Davies
t al.144 retrospectively reviewed 138 patients, 88% of whom were
reated with TTM. The use of antibiotics in the ﬁrst week of
dmission was associated with reduced mortality (56.6% vs. 75.3%; = 0.025).
The committee found the retrospective nature of the evidence
nsufﬁcient to support the routine use of antibiotics, but the Davies
rticle is provocative and the issue requires further study.ion 98 (2016) 48–63
We  recommend against the use of procalcitonin (PCT) for the
diagnosis of infection in patients treated with TTM.
Quality of evidence: Low
Strength of recommendation: Strong
There has been increasing interest in the utility of PCT for the
diagnosis of infection and for guiding antibiotic utilization. PCT has
been retrospectively studied in TTM patients and found to be non-
speciﬁcally elevated.145,146
The potential harm from using a diagnostic test that appears to
have very low positive and negative predictive values led the com-
mittee to a strong recommendation despite the low overall quality
of evidence.
We suggest that standard order sets and care bundles be uti-
lized for the initiation and care of patients undergoing TTM.
Quality of evidence: Low
Strength of recommendation: Conditional
The committee found the overall quality of the evidence around
this issue to be low. Walters et al. implemented a care bun-
dle that included TTM and hemodynamic optimization targets.147
In a pre-post design of 55 patients, the implementation of the
care bundle was associated with a trend towards reduced mor-
tality and improved neurological outcome. Kilgannon et al.148
reported on the successful implementation of an order set for
TTM.
The committee concluded that although the use of these clinical
tools may  simplify the clinical application of TTM, there is currently
no good evidence of improved patient outcomes. Centers lacking
order sets and care bundles should continue to provide TTM while
the tools are developed.
Feeding
We  recommend that patients undergoing TTM receive
enteral nutrition.
Quality of evidence: Moderate
Strength of recommendations: Strong
We  suggest that caloric intake targets be calculated as 75% of
normothermic targets during the hypothermic phase of TTM, if
calorimetry is not being used.
Quality of evidence: Low
Strength of recommendations: Conditional
There were no high-quality studies that directly addressed the
issue of how much patients who are undergoing TTM should be
fed. The recommendation is based on extrapolation of nutrition
research for critically ill patients, studies from other populations,
and physiologic studies.
Three small observational studies compared indirect calorime-
try measurements to basal metabolic rate calculated by the
Harris–Benedict equation in patients undergoing TTM.149–151 All
were for indications other than post-cardiac arrest, the major-
ity of patients being victims of traumatic brain injury. Measured
energy expenditure was 71%, 70% and 85% that of calculated energy
expenditure. There was no high quality data on the effect of
TTM on absorption. A recent longitudinal cohort analysis suggests
patients undergoing TTM tolerate a signiﬁcant volume of enteral
feeds.152
The committee felt that there was sufﬁcient evidence suppor-
ting the use of enteral nutrition in other critically ill patients tomarginal expectation of beneﬁt for this time period. There were
concerns of harm if aggressive pursuit of enteral feeding was  to
be combined with prokinetic agents that may prolong the QTc
interval.
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ewarming
We  suggest that rewarming should begin 24 h after the
atient reaches the target temperature.
Quality of evidence: Low
Strength of recommendation: Conditional
Eight RCTs1,2,8,43,104,115,117,153 informed this recommendation.
one of the studies addressed the clinical question with a direct
omparison. The reference point for the start of the rewarming
eriod was variable amongst the studies and included time from
ospital arrival, time from start of cooling procedures, and time
rom achievement of target temperature (TT).
In four RCTs, rewarming was commenced 24 h after achieve-
ent of TT.2,115,117,153 Laurent et al.,43 randomized 61 patients
nto 3 groups (hemoﬁltration, hemoﬁltration with hypothermia,
nd control). Cooled patients were passively rewarmed after 16 h
f hypothermia. In the Bernard trial1rewarming began 18 h after
rrival to hospital. In a study assessing the feasibility of a hel-
et  cooling device,104 16 patients were cooled while 14 received
ormothermia. In the helmet group, participants were allowed to
pontaneously rewarm over an 8-h period after achieving TT or
fter 4 h, whichever came ﬁrst. In the Nielsen trial8 passive rewarm-
ng commenced 28 h after the start of cooling. A recently published
ystematic review and meta-analysis of RCTs, observational stud-
es, and case reviews summarizes the evidence on duration of
ooling.140 The majority (74%) of included studies report 24 h of
ypothermia.
The committee’s consensus was that patients be kept at the
arget temperature for 24 h, but acknowledged that the quality of
he evidence was low due to limitations in design, inconsistency
n application, and indirectness of the ﬁndings. The committee
dentiﬁed concerns of potential harm due to infection from more
rolonged hypothermia. Moreover, there was signiﬁcant debate
bout whether shorter time periods might also be acceptable in
ertain clinical situations. The low quality of evidence led to the
onditional recommendation.
We  suggest that patients should be rewarmed at a rate of
.25–0.5 ◦C Celsius per hour.
Quality of evidence: Low
Strength of recommendation: Conditional
The review did not ﬁnd any high level evidence that directly
ddressed this issue. A retrospective cohort study by Bouwes154
ompared patients who were rewarmed at a rate ≥0.5 ◦C to <0.5 ◦C
nd found a non-signiﬁcant trend toward poor outcome in the
apidly warmed patients (OR 2.61, p = 0.08).
Achieving consensus on this recommendation was challenging.
he quality of the evidence was low, and there was  signiﬁcant
ractice variation amongst committee members. There was gen-
ral agreement that rewarming should be controlled, if available
ethods of temperature control allow for this. There was con-
ern of harm from patients overshooting normothermia when
armed at a rapid rate. The committee felt there was insufﬁ-
ient evidence to recommend a speciﬁc rewarming method or
evice.
We suggest that hyperthermia (core temperature > 37.5 ◦C)
hould be prevented for at least 72 h post arrest.
Quality of evidence: Low
Strength of recommendation: Conditional
There is no direct evidence to support a recommendation on
ever management in this population. In the recent RCT by Nielsen
nd colleagues, the protocol advised fever control measures be used
n a site-speciﬁc basis to maintain body temperature at or below
7.5 ◦C for 72 h post-arrest.
Harm has not been demonstrated from fever in this popu-
ation. Amongst 177 patients in a prospective cohort of TTM
ost cardiac arrest,155 fever (>38 ◦C) was prevalent (76%) but notion 98 (2016) 48–63 59
associated with in-hospital mortality (p = 0.45). In the retrospec-
tive study by Bouwes et al.,154 development of fever within
72 h of admission was not associated with poor neurologic
outcome (OR 0.64 (0.31–1.30), p = 0.22). This ﬁnding was  con-
sistent after adjustment for confounders (OR 0.94 (0.40–2.17),
p = 0.88). In a retrospective, multicenter clinical registry study
Leary et al.156 found rebound pyrexia in 41% of TTM-treated
patients but no association with lower survival to discharge
(54% versus 52%, p = 0.88) or worsened neurologic outcomes
(70% versus 82%, p = 0.21). However, among patients with
fever, higher maximum temperature (>38.7 ◦C) was  associated
with worse neurologic outcomes among survivors to hospital
discharge.
The committee found the quality of evidence around this issue
to be low. Despite the lack of demonstrated harm from pyrexia
in this patient population, the committee considered indirect evi-
dence from other populations with neurologic injury.157–159 The
potential for beneﬁt, lack of harm, societal value of neurologic out-
come, low cost and feasibility of fever prevention led the committee
to suggest avoidance of hyperthermia.
Prognostication
We  recommend that a clinical neurologic examination for
the purpose of prognostication not be performed earlier than
72 h after return of spontaneous circulation.
Quality of evidence: Moderate
Strength of recommendation: Strong
We suggest that when there is a concern of residual medica-
tion effect, clinical neurologic examination for prognostication
should be deferred until the clinician is conﬁdent that the con-
founding effects are no longer present.
Quality of evidence: Low
Strength of recommendation: Conditional
Three recent meta-analyses have addressed neurological prog-
nosis after TTM.160–162
The current evidence suggests that the longer we wait, the more
speciﬁc diagnostic tests become at predicting a poor neurological
outcome.163,164 72 h after ROSC, many of the simple bedside clinical
exams predict poor neurological outcome with a false positive rate
approaching 0% with narrow conﬁdence intervals.160,165
Studies evaluating elements of the prognostic neurologic exam-
ination in TTM patients have found the most useful clinical exam
ﬁndings are bilaterally absent pupillary reﬂexes or bilaterally
absent corneal reﬂexes.160,166 At the recommended time 72 h after
ROSC, the presence of either ﬁnding is sufﬁcient to predict a
poor outcome, deﬁned as a Cerebral Performance Category (CPC)
3–5.
Sedation is recommended for patients undergoing TTM, but
has increasingly been shown to alter the accuracy and recom-
mended timing of the tests commonly used to predict neurological
outcomes.167 Samaniego et al. observed that 83% of TTM patients
in their study had received sedation within 12 h of their 72 h pro-
gnostic neurologic exam.127
The committee gave particular consideration to societal con-
cerns around false prognosis of poor outcome. This was balanced
with resource costs and emotional toll on family members that
come from a prolonged time interval. The committee reached
consensus for a strong recommendation that prognostication be
delayed for a minimum of 72 h after ROSC.
In situations where there is suspicion of residual drug effect at
72 h we  suggest extending the timing of these diagnostic tests. The
duration of the extension will depend on the sedatives and anal-
gesics used, their dosing, and the patient’s ability to clear them.
Any patient requiring ongoing sedation should not have prognostic
assessments for the purpose of limiting therapy.
6 scitat
t
e
s
r
w
a
a
s
h
a
p
e
i
b
T
E
t
p
n
i
s
t
t
c
s
c
a
D
u
W
t
T
e
p
m
a
p
w
n
c
f
m
b
a
m
A
b
e0 D. Howes et al. / Resu
We  suggest that adjunctive testing is not routinely required
o identify poor neurological outcome in patients after TTM
Quality of evidence: Low
Strength of recommendation: Conditional
We suggest that somatosensory evoked potentials (SSEP) and
lectroencephalography (EEG) can facilitate prognostication in
peciﬁc circumstances.
Quality of evidence: Low
Strength of recommendation: Conditional
Given the predictive accuracy of delayed clinical testing (corneal
eﬂexes and pupillary reﬂexes) at 72 h post-arrest, combined
ith the limited availabilities of advanced neuromodalities such
s SSEP and continuous EEGs, the committee chose to suggest
gainst the routine use of adjunctive testing. In certain circum-
tances, however, these modalities may  offer beneﬁt. SSEP testing
as demonstrated high speciﬁcity 24 h post-cardiac arrest,160,161
nd its prognostic results improve 72 h post-arrest.160,165 For the
urposes of prognostication, the only deﬁnitive SSEP result is bilat-
rally absent N20 responses. All other ﬁndings are considered
ndeterminate.
EEG has a marginally higher false positive rate than SSEP,160,165
ut may  still provide useful information in some circumstances.
he only acceptable result for prognostication is “unfavorable
EG”, deﬁned by at least one of burst suppression pat-
ern, status epilepticus, generalized suppression, or unreactive
attern.160
There is insufﬁcient data on the use of CT or MRI, and we do
ot recommend that either be used for prognostication. Most stud-
es are small with low precision estimates and a high likelihood of
election bias.160,165
We  recommend that a neurologic consultation is not rou-
inely required for prognostication.
Quality of evidence: low
Strength of recommendation: Strong
There was no evidence upon which to base this recommenda-
ion. The committee based its recommendation on the ability of
linicians caring for cardiac arrest patients to perform simple bed-
ide clinical examinations and the lack of access to timely specialty
onsultation in most centers.
Specialist consultation may  be very helpful in some situations
nd is encouraged in complex or confounded situations.
iscussion
The recommendations that we have developed for the
se of TTM after cardiac arrest build on previous work.168
e  address issues faced by clinicians, with recommenda-
ions based on comprehensive systematic literature reviews.
he committee also considered societal values, clinical ben-
ﬁt, risk of harm, cost, feasibility and variations in clinical
ractice environment. The guidelines were developed using GRADE
ethodology,7 with consideration of the AGREE II instrument14
nd guideline attributes most highly valued by emergency health
ractitioners.169
There are important strengths to this guideline. This guideline
as developed by a multidisciplinary committee, which included
urses, dietitians and physicians with specialty training in critical
are, emergency medicine and neurology. Representatives from the
our sponsoring Societies were involved at all stages of develop-
ent. Extensive efforts were made to avoid conﬂict of interest and
ias. Because one of our main objectives was to develop a practical
nd clinically useful guideline, we endeavored to offer a recom-
endation for each clinical question despite low quality evidence.
 signiﬁcant number of the recommendations are informed by or
ased on expert opinion, and where this is the case it is transpar-
ntly indicated.ion 98 (2016) 48–63
The guideline is limited to the use of targeted temperature man-
agement after cardiac arrest in adults. We  did not consider its use
in other clinical situations, or in the pediatric age group. The deﬁ-
nitions used by the committee to assign quality of evidence (Fig. 2)
have been updated.170 The revised deﬁnitions improve the clarity
of the terms, but do not substantively change their meaning.
Implementation of the recommendations made within this
guideline will require active dissemination strategies and
education.171,172 It is beyond the scope of this paper to provide such
strategies. However, it is the intention of the group to provide tools
for implementation that can be shared among the broader commu-
nity. Ideally, clinicians would be best served by a ‘living guideline’
that is continuously maintained and updated. The challenges of cre-
ating such a clinical tool include ﬁnding a home for the document,
ongoing ﬁnancial support, and contributor fatigue. In the face of
those limitations it is our intention to update the guideline every
ﬁve years.
Overall, we found that the majority of questions the clinicians
we surveyed had about the application of TTM have not been clearly
answered by the research. There are many clinical questions yet to
be adequately addressed, but there are some fundamental knowl-
edge gaps that should be prioritized by researchers. These include
patient selection, optimal cooling rate, optimal target temperature,
duration of hypothermia, and optimal rewarming rate.
Conclusions
Targeted temperature management (also referred to as
therapeutic hypothermia) is an important component of post-
resuscitation care for the patient with return of spontaneous
circulation after cardiac arrest. We  have provided clinically relevant
recommendations for the provision of this therapy in the emer-
gency department and critical care unit, and for prognostication
after its use.
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